Recent patents in the discovery of small molecule inhibitors of JAK3

Bibliography

• Ihle J, Kerr IM. Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet 1995;11:69
   PubMed Web of Science ®Google Scholar
• Pesu M, Laurence A, Kishore N, Therapeutic targeting of Janus kinases. Immunol Rev 2008;223:132
   PubMed Web of Science ®Google Scholar
• Kawahara A, Minami Y, Miyazaki T, Critical role of the interleukin 2 (IL-2) receptor gamma-chain-associated Jak3 in the IL-2 induced c-fos and c-myc, but not bcl-2, gene induction. Proc Natl Acad Sci USA 1995;92:8724
   PubMed Web of Science ®Google Scholar
• Villa A, Sironi M, Macchi P, Monocyte function in a severe combined immunodeficient patient with a donor splice site mutation in the Jak3 gene. Blood 1996;88:817
   PubMedGoogle Scholar
• Buckley RH, Schiff RI, Schiff SE, Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J Pediatr 1997;130:378
   PubMed Web of Science ®Google Scholar
• Nosaka T, van Deursen JMA, Tripp RA, Defective lymphoid development in mice lacking Jak3. Science 1995;270:800
   PubMed Web of Science ®Google Scholar
• Malaviya R, Uckun FM. Genetic and biochemical evidence for a critical role of Janus Kinase (JAK)-3 in mast cell-mediated type I hypersensitivity reactions. Biochem Biophys Res Commun 1999;257:807
   PubMed Web of Science ®Google Scholar
• Papageorgiou AC, Wikman LEK. Is JAK3 a new target for immunomodulation-based therapies. Trends Pharm Sci 2004;25:558
   PubMed Web of Science ®Google Scholar
• Pernis A, Witthuhn B, Keegan AD, Interleukin 4 signals through two related pathways. Proc Natl Acad Sci USA 1995;92:7971
   PubMed Web of Science ®Google Scholar
• Murray PJ. The JAK-STAT signaling pathway: input and output integration. Immunology 2007;178:2623
   Google Scholar
• Rodig SJ, Meraz MA, White JM, Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 1998;93:373
   PubMed Web of Science ®Google Scholar
• Rokosz LL, Beasley JR, Carroll CD, Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges. Expert Opin Ther Targets 2008;12:883.1
   Google Scholar
• Uckun FM, Malavia R, Sudbeck EA. JAK-3 inhibitors for treating allergic disorders. US6080747A; 2000
   Google Scholar
• Navara CS, Mahajan S, Uckun FM. Therapeutic uses of quinazoline derivatives as JAK3 kinase inhibitors. WO2000010981A1
   Google Scholar
• Uckun FM. Preparation of quinazoline derivatives as JAK-3 kinase inhibitors and their therapeutic uses. US2003149045A1
   Google Scholar
• Larsson J, Sjoe P. Preparation of novel 4-anilinoquinoline-3-carboxamides as JAK3 kinase inhibitors. WO2002092571A1
   Google Scholar
• David L, Gustafsson J, Lawitz K, Preparation of quinoline-3-carboxamides as JAK3 kinase modulators, particularly inhibitors. WO2005075429A1
   Google Scholar
• Bemis GW, Duffy JP. Quinoxalines useful as inhibitors of protein kinases. WO2005056547A2
   Google Scholar
• Gerspacher M, Furet P, Vangrevelinghe E, Preparation of quinoxalines, particularily heterocyclyl-substituted diarylquinoxalines, as inhibitors of the tyrosine kinase activity of Janus kinases for use in the treatment of immune and proliferative disorders. WO2008148867A2
   Google Scholar
• Green J, Aronov A, Pierce AC. Preparation of substituted chromen-4-one oximes as inhibitors of protein kinases. US2004198750A1
   Google Scholar
• Blumenkopf TA, Flanagan ME, Brown MF, Changelian PS. Preparation of pyrrolo[2,3-d]pyrimidines as inhibitors of protein tyrosine kinases such as Janus kinase 3. WO9965909A1
   Google Scholar
• Blumenkopf TA, Flanagan ME, Brown MF, Changelian PS. Preparation of pyrrolo[2,3-d]pyrimidines as immunosuppressive agents. WO9965908A1
   Google Scholar
• Blumenkopf TA, Flanagan ME, Munchhof MJ. Synthesis of pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases. WO2001042246A2
   Google Scholar
• Blumenkopf TA, Flanagan ME, Munchhof MJ. Preparation of pyrrolo[2,3-d]pyrimidines as immunosuppresive agents. WO2002000661A1
   Google Scholar
• Flanagan ME, Li ZJ. Preparation of a novel crystalline compound useful as inhibitors of protein kinases. WO2003048162A1
   Google Scholar
• Changelian PS. Method of treatment of atherosclerosis using pyrrolo[2,3-d]pyrimidine compounds inhibiting JAK3 kinase. US2005113395A1
   Google Scholar
• Changelian PS. Preparation of pyrrolopyrimidines as method of treatment of transplant rejection. WO2005060972A2
   Google Scholar
• Rodgers JD, Wang HC, Andrew P, Sparks RB. Pyrrolo[2,3-b]pyridine-4-yl-amines and pyrrolo[2,3-b]pyrimidin-4-yl-amines as Janus kinase inhibitors and their preparation, pharmaceutical compositions and use for treatment of diseases. WO2006069080A2
   Google Scholar
• Rodgers JD, Shepard S, Maduskuie TP, Preparation of heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors. US2007135461
   Google Scholar
• Rodgers JD, Shepard S, Maduskuie TP Jr, Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b] pyrimidines as Janus kinase inhibitors and their preparation and use in the treatment of diseases. US2009181959A1
   Google Scholar
• Rodgers JD, Shepard S, Li Y-L, Preparation of azetidine and cyclobutane derivatives as JAK inhibitors. WO2009114512A1
   Google Scholar
• Noronha G, Cao J, Chow C, Preparation of alkynyl pyrrolopyrimidine compounds as JAK kinase inhibitors. WO2009055674A1
   Google Scholar
• Guerin DJ, Jung J, Stanton E. JAK kinase inhibitors for the treatment of myeloproliferative disorders or cancer. WO2009054941A1
   Google Scholar
• Gaul C, Gerspacher M, Holzer P, Pissot SC. Preparation of pyrrolo[2,3-d]pyrimidines as tyrosine kinase, especially JAK kinase inhibitors. WO2009098236A1
   Google Scholar
• Dubois DJ, Hendricks RT, Hermann JC, Preparation of pyrrolopyrazines as JAK and SYK inhibitors. US2009215724A1
   Google Scholar
• Bamberg JT, Bartlett M, Dubois DJ, Preparation of pyrrolopyrazines as JAK and SYK inhibitors. US2009215750A1
   Google Scholar
• Dubois DJ, Elworthy TR, Hendricks RT, Preparation of pyrrolopyrazines as JAK and SYK inhibitors. US2009215785A1
   Google Scholar
• Elworthy TR, Hendricks RT, Kondru RK, Preparation of pyrrolopyrazines as JAK and SYK inhibitors. US2009215788A1
   Google Scholar
• David L, Hansen P. Azaindole compounds as Janus kinase 3 (JAK3 kinase) inhibitors, and their preparation, intermediates, and pharmaceutical compositions. WO2004099205A1
   Google Scholar
• Salituro F, Farmer L, Bethiel R, Preparation of azaindoles as inhibitors of JAK and other protein kinases. WO2005095400A1
   Google Scholar
• Pierard F, Jimenez J-M, Kengtel R, Preparation of azaindoles as inhibitors of protein kinases. WO2006004984A1
   Google Scholar
• Farmer L, Martinez-Botella G, Pierce A, Azaindoles useful as inhibitors of Janus kinases and their preparation and use in the treatment of diseases. WO2007084557A2
   Google Scholar
• Sadiq S, Brenchley G, Charrier J-D, Preparation of azaindoles useful as inhibitors of kinases. WO2007059219A1
   Google Scholar
• Ledeboer M, Pierce A, Bemis G, Preparation of pyrrolopyrimidines as inhibtors of protein kinase. US2006183761A1
   Google Scholar
• Ledeboer MW, Wannamaker MW, Farmer LJ, Pyrrolopyridines useful as inhibitors of protein kinase and their preparation, pharmaceutical compositions. and use in the treatment of various diseases. WO2006127587A1
   Google Scholar
• Ledeboer MW, Messersmith D, Maltais F, Preparation of deazapurines as inhibitors of Janus kinases (JAK). WO2007117494A1
   Google Scholar
• Salituro F, Farmer L, Wang T, Deazapurines useful as inhibitors of Janus kinases and their preparation, pharmaceutical compositions and use in the treatment of various diseases. WO2007041130A2
   Google Scholar
• Jimenez J-M, Knegtel R, Charrier J-D, Preparation of pyrazolo[1,5-a]pyrimidines as inhibitors of protein kinases. WO2006052913A1
   Google Scholar
• Inoue T, Tanaka A, Nakai K, Preparation of heterocyclic compounds as Janus kinase 3 inhibitors. WO2007077949A1
   Google Scholar
• Inoue T, Tojo T, Morita M, Preparation of azolopyridines as inhibitors of JAK3 Janus protein kinase. WO2007007919A2
   Google Scholar
• Shirakami S, Inoue T, Mukoyoshi K, Preparation of fused pyridine derivatives as JAK3 inhibitors for treatment of autoimmnune disease, leukemia, etc. WO2008084861A1
   Google Scholar
• Salas SJ, Almansa RC, Soliva SR, Pyrrolopyrimidine derivatives as JAK3 inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO2008119792A1
   Google Scholar
• Song Y, Xu Q, Pandey A. Preparation of bicyclic heteroaryl compounds as therapeutic protein inhibitors. WO2009026107A1
   Google Scholar
• Salas SJ, Almansa RC, Soliva SR, Preparation of aminopurine derivatives as JAK3 kinase inhibitors. WO2008090181A1
   Google Scholar
• Hemmerling M, Klingstedt T. Imidazo and thiazolopyridines as JAK3 kinase inhibitors. WO2004099204A1
   Google Scholar
• Styles ML, Zeng J, Treutlein HR, Preparation of benzimidazolylazines and related compounds as selective JAK3 kinase inhibitors. WO2005066156A1
   Google Scholar
• Zhang G, Ren P, Wang X, Preparation of pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors. WO2007005673A1
   Google Scholar
• Ohlmeyer M, Bohnstedt A, Kingsbury C, Preparation of purine and imidazopyridine derivatives for immunosuppression. WO2006108103A1
   Google Scholar
• Ohlmeyer MJ, Bohnstedt AC, Kingsbury C, Preparation of purinones and imidazopyridinones as JAK3 kinase inhibitors useful as immunosuppressants. US2008287468A1
   Google Scholar
• Lu Y, Kingsbury C, Bohnstedt A, 8-Substituted 2-(benzimidazolyl)purine derivatives as immunosuppressants and their preparation, pharmaceutical compositions and use in the treatment of immune disease. WO2008043019A1
   Google Scholar
• Neagu I, Diller D, Kingsbury C, 6-Substituted 2-(benzimidazolyl)purine and purinone derivatives as immunosuppressants and their preparation, pharmaceutical compositions and use in the treatment of immune diseases. WO2008043031A1
   Google Scholar
• Ohlmeyer MJ, Bohnstedt AC, Kingsbury C, Preparation of 7-substituted purine derivatives as inhibitors of tyrosine kinase JAK3 for immunosuppression. US2008119496A1
   Google Scholar
• Kingsbury C, Ohlmeyer MJ, Paradkar VM, Preparation of 2,7,9-substituted purinone derivatives as selective Jak3 inhibitors useful for immunosuppression. WO2009048474A1
   Google Scholar
• Ledeboer M, Davies RJ, Messersmith D, Preparation of benzisoxazoles useful as inhibitors of protein kinases. WO2004058749A1
   Google Scholar
• Gerspacher M, Furet P, Vangrevelinghe E. Benzoxazoles and oxazolopyridines as Janus kinases inhibitors and their preparation, pharmaceutical compositions and use in the treatment of tumor. WO2008031594A1
   Google Scholar
• Bourke DG, Burns CJ, Cuzzupe AN, Preparation of substituted thienopyrimidine deriatives and analogs for use as JAK kinase inhibitors. WO2009062258A1
   Google Scholar
• Bethiel RS, Ledeboer M. Preparation of phenylaminopyrimidines useful as inhibitors of JAK and other protein kinases. US2004097504A1
   Google Scholar
• Bethiel RS, Moon YC. Pyridine and pyrimidine derivatives and their compositins, useful as inhibitors of JAK and other protein kinases. WO2004041810A1
   Google Scholar
• Ledeboer M, Ledford B. Pyridine and pyrimidine derivatives and their compositins, useful as inhibitors of JAK and other protein kinases. WO2004041789A1
   Google Scholar
• Straub J, Hale MR, Maltais F, Preparation of pyrimidinyl/ triazinyl-substituted protein kinase inhibitors. WO2005068468A2
   Google Scholar
• Fraysse D, Miller A, Robinson D, Pinder J. Aminopyrimidines useful as kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer. WO2007059299A1
   Google Scholar
• Wannamaker M, Salituro F, Pierce A, Heteroaryl-substituted aminopyrimidine compounds useful as inhibitors of Janus kinases and their preparation. WO2008116139A2
   Google Scholar
• Duthaler R, Gerspacher M, Holzer P, Preparation of 2,4-di(arylamino)-pyrimidine-5-carboxamides as JAK kinases inhibitors. WO2008009458A1
   Google Scholar
• Wong B. 2,4-Pyrimidinediamine compound JAK kinase inhibitors, and their therapeutic use. US2006270694A1
   Google Scholar
• Li H, Thota S, Carroll D, Preparation of pyrimidine-2,4-diamines for inhibition of the JAK pathway. WO2006133426A2
   Google Scholar
• Li H, Argade A, Tso K, Preparation of pyrimidine-2,4-diamines for inhibition of the JAK pathway. WO2007098507A2
   Google Scholar
• Argade A, Sran A, Carroll D, Preparation of pyrimidine-2,4-diamines for inhibition of the JAK pathway. US2007203161A1
   Google Scholar
• Atuegbu A, Markovtsov V, Bhamidipati S, Pyrimidinediamine derivatives as JAK kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO2008118823A2
   Google Scholar
• Li H, Argade A, Thota S, Preparation of 2,4-pyrimidinediamine derivatives as JAK kinase inhibitors. WO2008049123A2
   Google Scholar
• Argade A, Sran A, Carroll D, Preparation of pyrimidine-2,4-diamines for the inhibition of the JAK pathway. WO2008079907A1
   Google Scholar
• Li H, Taylor V, Bhamidipati S, Pyrimidinediamine derivatives as JAK kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO2008118822A1
   Google Scholar
• Burns CJ, Kling MR. A preparation of nicotinamide based tyrosine kinase inhibitors. WO2004054977A1
   Google Scholar
• Kling MR, Burns CJ. Pyridine derivatives, processes for preparaing them, pharmaceutical compositions containing them, and their use as selective kinase inhibitors. WO2007062459A1
   Google Scholar
• Bourke DG, Bu X, Burns CJ, Preparation of arylthiopyrimidines as JAK kinase inhibitors. WO2008092199A1
   Google Scholar
• Burns CJ, Palmer JT, McNally M. Preparation of 2-anilino-4-phenylpyrimidines as retrometabolic drugs for treatment of immunological or inflammatory disease, pulmonary aterial hypertension, asthma, chronic obstructive pulmonary disease, and cancer. WO2009029998A1
   Google Scholar
• Noronha G, Mak CC, Cao J, Preparation of anilinopyrimidines as jak kinase inhibitors. WO2009046416A1
   Google Scholar
• Wilks AF, Bu X, Burns CJ. Preparation of imidazolylpyrazines as protein kinase inhibitors for treatment of receptor type tyrosine kinase-related diseases. WO2003099811A1
   Google Scholar
• Burns CJ, Bu X, Wilks AF. Preparation of Phenylpyrazines as protein kinase inhibitors for treatment of receptor type kinase-related diseases. WO2003099796A1
   Google Scholar
• Salituro F, Ledeboer M, Ledford B, Preparation of diaminotriazole derivatives as Janus kinases inhibitors for treatment of immune diseases. US2006063756A1
   Google Scholar
• ltman M, Christopher M, Grimm JB, 2-Aminothiophene-3-carboxamide derivatives as inhibitors of Janus kinases and their preparation and use in the treatment of myeloproliferative disorders and cancers. WO2008156726A1
   Google Scholar
• Wilson LJ, Murray WV, Yang S-M, Preparation of substituted indolo[2,3-a]pyrrolo[3,4-c]carbazole compounds useful in treating protein kinase-associated disorders. US2007249590A1
   Google Scholar
• Young JR, Haidle A, Tempest P, Machacek M. Preparation of benzoimidazoisoquinolines as inhibitors of Janus kinases. WO2007145957A1
   Google Scholar
• Siu T, Young JR, Altman M, Preparation of 7,8-fused-2,6-naphthyridin-1(2H)-ones as inhibitors of Janus kinases. WO2009035575A1
   Google Scholar
• Truchon J-F, Lachance N, Lau C, Preparation of tricyclic compounds useful as inhibitors of kinases. WO2007061764A2
   Google Scholar
• Young JR, Lim J, Machacek MR, Preparation of 5H-pyrido[4,3-b]indole derivatives as Janus kinases inhibitors. WO2009075830A1
   Google Scholar
• Jimenez J-M, Green J, Gao H, Preparation of aminopyrimidine derivatives as inhibitors of protein kinases. US2005148603A1
   Google Scholar
• Bennani Y, Wang T, Salituro F, Duffy J. Preparation of tricyclicheteroaryl derivatives for use as Janus kinase inhibitors. WO2008079521A2
   Google Scholar
• Ren P, Wu B, Zhang G, Preparation of substituted fused naphthyridines as protein kinase inhibitors. WO2007134259A2
   Google Scholar
• Rodgers JD, Robinson DJ, Arvanitis AG, Preparation of tetracyclic inhibitors of Janus kinases for treating immune-related diseases and cancer. WO2005105814A1
   Google Scholar
• Arvanitis AG, Rodgers JD, Combs AP, Preparation of tetracyclic inhibitors of Janus kinases. WO2007038215A1
   Google Scholar
• Wrobleski ST, Pitts WJ. Advances in the discovery of small molecule JAK3 inhibitors. Ann Rep Med Chem 2009;44:247
   Google Scholar
• The most recent study for compound 8 at the time of publication: “2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate.” Trial No. NCT00847613. Sponsor: Pfizer. Available from: www.clinicaltrials.gov
   Google Scholar
• Changelian PS, Flanagan ME, Ball DJ, Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003;302:875
   PubMed Web of Science ®Google Scholar
• Sorbera LA, Serradel N, Bolos J, CP-690550 JAK3 inhibitor immunosuppressant treatment of rheumatoid arthritis treatment of transplant rejection. Drugs Future 2007;32:674
   Google Scholar
• Van Gurp E, Weimar W, Gaston R, Phase 1 dose-escalation study of CP-690,550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics. Am J Transplant 2008;8:1711
   PubMed Web of Science ®Google Scholar
• Rigel Announces Initiation of Phase 1 Trial of R348 for Rheumatoid arthritis, Psoriasis and Other Immune Disorders. 9 January 2009. PRNewswire. Available from: www.rigel.com
   Google Scholar
• Deuse T, Velotta JB, Hoyt G, Novel immunosuppression: R348, a JAK3- and Syk-inhibitor attenuates acute cardiac allograft rejection. Transplantation 2008;85:885
   PubMed Web of Science ®Google Scholar
• Results of a Phase 1, 14-day dose ranging study of VX-509 in healthy volunteers completed in the first quarter suggested a promising safety profile. In this study, VX-509 showed a dose-dependent and reversible reduction in PSTAT-5, a specific biomarker of JAK3 activity, and a high degree of selectivity for JAK3 over JAK2, consistent with observations from previous in vitro studies. 11 August 2009. Available from: www.vrtx.com
   Google Scholar
• Lin Q, Meloni D, Pan Y, Enantioselective synthesis of Janus kinase inhibitor INCB018424. Org Lett 2009;11:1999
   PubMed Web of Science ®Google Scholar
• Incyte's JAK Inhibitor Demonstrates Marked Clinical Benefits in Phase IIa Rheumatoid Arthritis Study. 12 June 2008. Available from: www.incyte.com
   Google Scholar